Mr. Paul Reid:

The Deputy has called the situation as it is. We do not see that there will be an abundance of vaccine supply from Johnson & Johnson. Our second quarter projections indicate approximately 3.8 million vaccine doses being available from four suppliers, assuming the EMA approves the Johnson & Johnson vaccine. The assumption is that the Johnson & Johnson vaccine will make up about 600,000 doses of the total, and that will primarily-----